MedTrace Logo

BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation

NCT05622123 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-04-04

No results posted yet for this study

Summary

The main goal is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes

Conditions

Interventions

DRUG

68Ga-NODAGA-Exendin-4

PET/CT imaging after injection with 68Ga-NODAGA-exendin-4

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Martin Gotthardt, MD, Prof. · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-23
Primary Completion
2024-02-28
Completion
2024-03-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05622123 on ClinicalTrials.gov